drugset / Trial / NCT00143741

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

NCT00143741

Phase 1 Completed 20 enrolled University of Chicago
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to identify subjects who are highly sensitized with antibodies. It is difficult for these patients to find suitable kidneys. We propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.

Timeline

Start
2005-05
Primary completion
2010-12
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral